SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Recursion Pharmaceuticals amends Tempus master agreement, SEC filing

Recursion Pharmaceuticals entered an amendment to its master agreement with Tempus, disclosed via an SEC filing dated Sept 15, 2026.

RXRXTEM

Related stories